IBO Impact BioMedical, Inc.: Market Capitalization to Book Value Ratio

Impact BioMedical Inc (IBO) develops diversified biomedical solutions to combat oncology and viruses, leveraging unique patents. The market-to-book ratio allows for an assessment of the underlying asset reliability, where the level of 2.80 reflects the current magnitude. A stable operational foundation is ensured by the humanitarian status of the developments, while portfolio growth and technology commercialization are achieved through strategic licensing partnerships.

Impact BioMedical Inc (IBO) - Market Capitalization to Book Value Ratio from 09/17/2024 to 10/28/2026

The market-to-book ratio measures the gap between a business's market value and the value of its net assets. Investors utilize this coefficient to identify "value traps" when an asset appears superficially cheap. By analyzing the current dynamics of the market-to-book multiple, one can assess market confidence in a company's capital. For Impact BioMedical Inc (IBO), this is critical due to the dispersion of resources across numerous developments. A high risk of failed project commercialization could lead to a systemic degradation of the balance sheet.

Direct competitors

Market Value to Book Value Ratio Haleon plc (HLN)|kenvue.com (KVUE) - Market Capitalization to Net Assets|VRNA - Market Capitalization to Book Value Ratio|Market Value to Book Value Jyong Biotech Limited|Market Capitalization to Book Value Ratio LGND|Market Capitalization to Book Value Ratio AMRX (Amneal Corp)|Market Value to Book Value Ratio Perrigo Company plc|alvotech.com - Market Value to Book Value|LQDA: Market Value to Book Value Ratio|GLPG - Market Cap to Net Assets Ratio|ANIP: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Afrezza|AMPH - Market Cap to Net Assets Ratio|Market Value to Book Value PCRX|ARS Pharmaceuticals, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio Theravance Biopharma Inc TBPH|Market Cap to Net Assets Ratio Aquestive Pharma (AQST)|Market Cap to Book Value Multiple scPharmaceuticals, Inc. SCPH|Market Capitalization to Book Value Ratio Tectonic (TECX)|TNXP - Market Value to Book Value|Market Capitalization to Book Value Ratio SXTC|EPRX (Eupraxia Pharmaceuticals Inc.) - Market-to-Book Ratio|BHST - Market Value to Book Value Ratio|Market Value to Book Value Invizyne|ORMP (Oramed Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value ENTX (enterabio.com)|MindWalk Holdings Inc. - Market Value to Book Value Ratio|ABVC BioPharma Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Cumberland Pharma|QNTM - Market Capitalization to Net Assets|FGEN: Market Capitalization to Book Value Ratio|telomirpharma.com (TELO) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio RANI|Market Cap to Net Assets Ratio Synergy CHC Corporation (SNYR)|Market Cap to Net Assets Ratio Rallybio Corporation|Market Cap to Book Value Multiple lexariabioscience.com LEXX|Market Cap to Net Assets Ratio Pulmatrix, Inc.|Market Value to Book Value Pheton Holdings Limited PTHL|APM - Market Capitalization to Book Value Ratio|LYRA - Market Value to Book Value Ratio|tnfpharma.com - Market Capitalization to Book Value Ratio|YCBD (cbdMD) - Market Capitalization to Book Value|Market Value to Book Value Ratio PRFX (PainReform Ltd.)|Market-to-Book Ratio CYTO|Market Value to Book Value Ratio LIPO (Lipella Pharmaceuticals, Inc.)|Market Cap to Net Assets Ratio OptiNose Inc (OPTN)|PIRS: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Procaps Group Corp PROC|Petros Pharmaceuticals (PTPI) - Market Capitalization to Book Value Ratio|QLI - Capitalization to Book Value Ratio|ACELYRIN - Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Book Value